November 11, 2020 | Media Coverage

Epidermolysis Bullosa News

1st Patient Treated in Phase 3 Trial of RDEB Gene Therapy, D-Fi

Read More

October 29, 2020 | ~Home Feature| Media Coverage

Cell & Gene

Castle Creek Biosciences’ D-Fi To Be Manufactured At In-House cGMP

Read More

October 28, 2020 | ~Home Feature| Press Release

Castle Creek Biosciences Announces First Patient Dosed in DeFi-RDEB Phase 3 Clinical Trial of Debcoemagene Autoficel (D-Fi) Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

Company manufacturing and distributing D-Fi at in-house, cGMP commercial-scale facility in greater Philadelphia area

Read More

October 20, 2020 | ~Home Feature| Media Coverage

Scleroderma News

First Patient Treated in Trial Testing FCX-013 Gene Therapy for Localized Scleroderma

Read More

October 15, 2020 | ~Home Feature| Press Release

Castle Creek Biosciences Announces First Patient Dosed in Phase 1/2 Clinical Trial of FCX-013 Gene Therapy for Treatment of Moderate to Severe Localized Scleroderma

Study targets a chronic autoimmune skin disorder affecting approximately 50,000 patients in the U.S.

Read More

October 06, 2020 | Events

Rare Disease Innovation and Partnering Virtual Summit 2020

Read More

September 06, 2020 | Events

Fall Clinical Dermatology Meeting 2020

Read More

August 06, 2020 | Events

2020 Pediatric Dermatology Research Alliance (PeDRA) Annual Conference

Read More

May 09, 2020 | Media Coverage

Philadelphia Magazine’s NextHealth PHL

9 Philly Companies on the Cutting Edge of Cell and Gene Therapy Innovation

Read More

May 06, 2020 | Events

2020 Virtual Cell & Gene Meeting on the Mesa

Read More